Traws Stock Rises 24% on Avian Flu Drug Update (TRAW:NASDAQ)


The concept of avian influenza pandemic. A test tube with a blood test for bird flu h5n1. Chicken disease control.

Diy13/iStock via Getty Images

The shares of Traws Pharma (NASDAQ:GRASS) soared 24% in after-market trading Friday on encouraging results from a Phase 1 study of the company’s drug Tivoxavir Marboxil in the treatment of H5N1 bird flu.

The study showed a single dose of



Source link

  • Related Posts

    Arcellx CFO Michelle Gilson sold shares worth $700,959 Via Investing.com

    Following these transactions, Gilson held 9,582 shares of Arcellx common stock. Sales include broker-assisted transactions to cover tax obligations associated with the vesting of restricted stock units. The company maintains…

    Rumble Announces Cloud Agreement with Government of El Salvador

    Rumble Announces Cloud Agreement with Government of El Salvador Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *